Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
- PDF / 1,096,982 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 17 Downloads / 172 Views
Open Access
RESEARCH
Dosing of thromboprophylaxis and mortality in critically ill COVID‑19 patients Sandra Jonmarker1,2, Jacob Hollenberg3, Martin Dahlberg1,4, Otto Stackelberg1,4,5, Jacob Litorell2, Åsa H. Everhov1,4, Hans Järnbert‑Pettersson1, Mårten Söderberg1,6, Jonathan Grip7,8, Anna Schandl2,9, Mattias Günther1,2 and Maria Cronhjort1,2*
Abstract Background: A substantial proportion of critically ill COVID-19 patients develop thromboembolic complications, but it is unclear whether higher doses of thromboprophylaxis are associated with lower mortality rates. The purpose of the study was to evaluate the association between initial dosing strategy of thromboprophylaxis in critically ill COVID19 patients and the risk of death, thromboembolism, and bleeding. Method: In this retrospective study, all critically ill COVID-19 patients admitted to two intensive care units in March and April 2020 were eligible. Patients were categorized into three groups according to initial daily dose of thrombo‑ prophylaxis: low (2500–4500 IU tinzaparin or 2500–5000 IU dalteparin), medium (> 4500 IU but 5000 IU but 4500 IU but 5000 IU but
Data Loading...
